Biotech
Commented by André Will-Laudien on March 25th, 2026 | 09:35 CET
Oil Volatility Shakes Markets – Life Sciences Stocks Back in Focus: Bayer, Vidac Pharma, Valneva, Novo Nordisk, and Pfizer
The conflicts in the Middle East continue. With the first talks between the US and Iran, the stock markets made a lightning-fast upward adjustment. As a result, the German benchmark index DAX 40 gained a full 1,600 points within just 10 minutes at the start of the week. However, it was unable to hold that level, falling back to 22,600 points yesterday. The question now is whether the parties to the conflict can actually reach a viable solution. Completely unfazed by the broader market conditions, some news is making waves in the life sciences sector, driving price movements here and there. It is good to shift the focus away from daily market fluctuations and toward other profitable sectors. Here are a few ideas.
Read
Commented by Fabian Lorenz on March 20th, 2026 | 09:00 CET
Which stock to buy now? Evotec, Nel, and Lahontan Gold in focus
What is driving Nel's sudden rebound? Within just a few days, the former hydrogen hopeful has surged more than 20% in value, breaking out of its short-term downtrend. Yet analysts do not see a trend reversal. Instead, they point to a risk in the order backlog. In contrast, the gold explorer Lahontan Gold currently offers an interesting entry opportunity following a sharp correction. The company aims to expand the resource estimate of its flagship Nevada project beyond 2 million ounces. If successful, the stock could be materially undervalued. Evotec, on the other hand, continues to struggle with investor sentiment. Even a recent milestone payment failed to provide positive momentum, with the stock declining further yesterday.
Read
Commented by Armin Schulz on March 20th, 2026 | 08:35 CET
Act Now! Invest in cancer research with BioNTech, Vidac Pharma, and Pfizer and secure returns
Global healthcare spending is surging, and the oncology sector promises above-average returns. As the global population continues to age, the number of new cancer cases is expected to rise to over 30 million annually by 2040, intensifying competition among pharmaceutical companies for market share in this trillion-dollar industry. However, it is not yesterday's established drugs that offer the greatest profit potential, but rather radical technological shifts. While BioNTech is now deploying its billion-dollar mRNA platform against tumors, Vidac Pharma is pursuing an entirely novel approach aimed at starving cancer cells. At the same time, Pfizer is pushing aggressively into this field. We take a closer look at the current situation of these three companies.
Read
Commented by Fabian Lorenz on March 16th, 2026 | 09:05 CET
BioNTech a Takeover Target? What's Happening at CHAR Technologies and Steyr Motors?
A cleantech growth story with takeover potential is currently available for only around CAD 35 million. CHAR Technologies is benefiting from rising oil and gas prices thanks to its technology. If the stock fails to move higher, a strategic partner could step in. Is BioNTech a takeover candidate? Until last week, the answer would likely have been a clear no. But since the announcement that the founders are stepping down, almost anything seems possible. And there is another factor in its favor. To avoid being swallowed by a major defense contractor, Steyr Motors aims to grow aggressively - both organically and through acquisitions. Analysts believe the company could double its revenue and recommend buying the stock.
Read
Commented by André Will-Laudien on March 13th, 2026 | 08:35 CET
Bull market or bear market? Not all that glitters is gold! Evotec, TeamViewer, and Lahontan Gold under review
With volatility at current levels, investors are looking for stable stocks. That is not easy, because on days when oil prices start the morning with a USD 35 premium, stocks are sometimes sold off in a panic. This is a paradise for traders, an opportunity for long-term investors, and a costly mistake for the nervous. This is how modern stock markets operate: AI-driven trading algorithms anticipate possible scenarios based on volatility patterns and reshape order books within milliseconds. For private investors, the key is to keep their nerve and separate the wheat from the chaff. We take a closer look at Evotec, TeamViewer, and Lahontan Gold. Because where there is light, there is also shadow.
Read
Commented by Fabian Lorenz on March 12th, 2026 | 07:25 CET
Breaking News! Takeover speculation? BioNTech, Evotec, Vidac Pharma
First, the positive news: Vidac Pharma's drug candidate VDA-1102 was recently used in a compassionate treatment case in connection with a girl's third brain surgery. Following the treatment, the patient's condition improved significantly. In addition, the Vidac platform is now being tested beyond oncology. 2026 could mark a potential breakthrough year for the company and its stock. It was a different story this week for BioNTech, whose shares suffered a sharp setback. The rather mixed results for 2025 and the cautious outlook for the current year likely played only a limited role. More troubling for shareholders is likely the impending departure of the founding couple. This raises the question: Could BioNTech become a takeover target? There were also long faces at Evotec this week. The company's restructuring program has failed to convince the market, and the stock has slipped below an important technical support level.
Read
Commented by André Will-Laudien on March 12th, 2026 | 07:05 CET
Sector rotation favors biotech and life sciences! BASF, MustGrow, Novo Nordisk, and BioNTech in focus
Surprises are currently widespread. Former Agriculture Minister Cem Özdemir will now lead the state parliament in Baden-Württemberg. The Green Party won over 30% of the vote in a landslide victory, putting issues such as environmental protection, social affairs, and, from Mr. Özdemir's time as minister, the agricultural industry back in the spotlight. With a human-centered approach and a focus on healthy nutrition, this means that established agricultural companies are increasingly being forced to reconcile productivity with sustainability. In this environment, MustGrow Biologics is positioning itself as a strategic technology provider whose achievements have already been validated by leading market players. An expanded sector view also includes the life sciences industry with the protagonists BASF, Novo Nordisk, and BioNTech - an exciting mix.
Read
Commented by Armin Schulz on March 9th, 2026 | 07:05 CET
Top Dividend Stocks: With Novo Nordisk, RE Royalties, and SAP, investors reap where others only see risk
Markets are currently oscillating between fears of war and hopes for interest rate cuts. While geopolitics and economic data continue to fuel uncertainty, many investors are turning back to a proven principle: reliable dividends. March 2026 highlights how fragile global growth can be when the Strait of Hormuz turns into a geopolitical powder keg and even the IMF warns of new economic shocks. In this tense environment between acute crisis and the search for stable returns, companies with dependable dividend policies are gaining importance. Against this backdrop, we take a closer look at Novo Nordisk, whose dividend stability must prove itself in an increasingly competitive pharmaceutical market, RE Royalties, which offers a remarkably high yield, and SAP, which recently surprised investors with a dividend increase.
Read
Commented by Nico Popp on March 3rd, 2026 | 07:40 CET
Paradigm shift in oncological dermatology: Vidac Pharma as an innovator, what are Almirall and Biofrontera doing?
Oncological dermatology is on the cusp of a revolution that could fundamentally change our understanding of cancer treatment. Persistence Market Research estimates that the global market for the treatment of actinic keratosis will reach a volume of around USD 7 billion by 2026. Analysts expect the market to grow to between USD 11.1 and 14.45 billion by the mid-2030s. This momentum is driven by the aging global population, cumulative UV exposure due to changing leisure habits, and increased awareness of the dangers of skin cancer. Currently, established industry giants such as Almirall and Biofrontera dominate the standard of care for actinic keratosis with their proven products. However, Vidac Pharma marks the transition from merely combating symptoms to a revolutionary procedure in oncological dermatology. This makes the company an opportunity for growth-oriented investors seeking access to a completely new class of drugs in the field of metabolic oncology.
Read
Commented by Fabian Lorenz on March 2nd, 2026 | 07:20 CET
Will the Iran conflict fuel gold prices? Iamgold and Lahontan Gold stand to benefit! Novo Nordisk shares poised for a rebound?
Will tensions in Iran push gold to new highs? At the very least, the crisis currency is likely to see renewed demand, and with it, gold stocks. Iamgold demonstrates that industry does not necessarily rely on rising gold prices to generate strong profits. Expectations for the gold producer's quarterly figures were high. Can the 50% rally continue? Lahontan Gold is currently in a pivotal phase. Its historical resource of just under 2 million ounces is expected to increase following updated estimates. In addition, the construction of the first mine in the heart of the US gold region appears increasingly likely. This may be one of the last opportunities to accumulate the stock at an attractive price. By contrast, Novo Nordisk has lost considerable investor confidence. The shares appear inexpensive, but is another guidance cut looming? Some analysts believe the stock may have already found a bottom.
Read